Please assess the completion status of the following clinical trial:

Trial Title: Drug and Non-Drug Treatment Of Severe Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 65 years~* Diagnosis of migraine with or without aura (International Classification of Headache Disorders)~* 3 or more migraine episodes/month with disability for the past 6 months~* Less than 20 total headache days/month for the past 6 months~Exclusion Criteria:~* Medication overuse headaches~* Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw~* Concurrently undergoing counseling/psychotherapy treatment~* Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.~* Unable/unwilling to give written informed consent~* History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease.~* Uncontrolled hypertension at screening (sitting systolic pressure \> 160 mmHg, diastolic pressure \> 95 mmHg)~* Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception.~* Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality.~* Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)~* Has a substance abuse problem or a psychological disorder that prevents participation in study (e.g., unmanaged severe depression that requires immediate treatment or limits participation in home-based treatment)~* Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol, Sumatriptan, or Rizatriptan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Optimal Acute Therapy plus Beta Blocker Placebo
- 2 (Type: ACTIVE_COMPARATOR): Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
- 3 (Type: ACTIVE_COMPARATOR): Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
- 4 (Type: ACTIVE_COMPARATOR): Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)

Based on this trial design, predict the completion outcome and termination type (if applicable).